Working… Menu

Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study) (LEUKO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00493974
Recruitment Status : Terminated (Lack of feasibility due to low recruitment)
First Posted : June 29, 2007
Results First Posted : March 3, 2010
Last Update Posted : November 18, 2019
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
University of Minnesota

Brief Summary:
Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that is caused by cigarette smoking or by breathing in other lung irritants, including pollution, dust, or chemicals. The purpose of this study is to evaluate the effectiveness of zileuton, a medication that is used to control asthma symptoms, at reducing the length of a hospital stay for adults who are hospitalized for a COPD exacerbation, or worsening of COPD symptoms.

Condition or disease Intervention/treatment Phase
Pulmonary Disease, Chronic Obstructive Drug: Zileuton Drug: Placebo Phase 3

Detailed Description:

COPD is a disease in which the lung airways are partly damaged and obstructed, making it difficult to breathe. COPD is the fourth leading cause of death in the United States. Symptoms include coughing, excess mucus production, shortness of breath, wheezing, and chest tightness. Treatment usually includes inhaled bronchodilator or steroid medications that work by relaxing the muscles around the lung airways and reducing inflammation. Zileuton, a medication that is used to prevent asthma symptoms, may be beneficial in treating people who experience COPD exacerbations. Zileuton works by blocking the formation of substances that cause inflammation, fluid retention, and constriction in the lungs. The purpose of this study is to evaluate the effectiveness of zileuton at reducing the length of a hospital stay for adults who are hospitalized for a COPD exacerbation.

This study will enroll adults who are admitted to the hospital due to severe COPD symptoms. Participants will be randomly assigned to receive either zileuton or placebo four times a day for up to 14 days. While in the hospital, lung function testing and urine collection will occur. Study visits will occur at Days 14 and 30, and will include lung function testing, a medical history review, and a study drug adverse effects review.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 119 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Antileukotriene Therapy for COPD Exacerbations
Study Start Date : March 2007
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Lung Diseases
Drug Information available for: Zileuton

Arm Intervention/treatment
Active Comparator: Zileuton
Zileuton (Zyflo, 600 mg 4 times a day)
Drug: Zileuton
Zyflo tablets, 600 mg, 4 times a day
Other Name: Zyflo

Placebo Comparator: Placebo
Drug: Placebo
Placebo 4 x daily
Other Name: Inactive Matching Placebo

Primary Outcome Measures :
  1. Length of Hospital Stay [ Time Frame: Measured at Day 30 ]
    Admission will begin at the time the subject has been admitted to an inpatient service. Length of Stay (LOS) will be recorded in days. The LOS will be based on the number of days spent in an acute medical ward or in the ICU. Subjects that are admitted and discharged in the same 24 hour period will be recorded as a LOS of 1 day, as will subjects discharged in the ensuing 24 hour period. LOS's greater than 10 days will be truncated to 10 days.

Secondary Outcome Measures :
  1. Change in FEV1% Predicted [ Time Frame: Measured at Baseline and Day 30 ]
    Change in Post-bronchodilator FEV1% predicted comparing data at 30 day visit with baseline.

  2. Change in FEV1/FEV6 Levels [ Time Frame: from baseline to day of discharge ]
    Change in Post-bronchodilator FEV1/FEV6 ratio comparing data at discharge visit with baseline.

  3. Treatment Failure [ Time Frame: Baseline to day 30 visit ]
    Treatment failure is defined as death, intubation, readmission to a hospital for COPD, urgent visit to an outpatient or ED provider for symptoms of COPD or intensification of therapy [including second course of antibiotics for COPD, and second course of systemic steroids for COPD]) in the first 30 days after randomization.

  4. Health-related Quality of Life [ Time Frame: Change from Baseline and 1 Month ]

    St. George's Respiratory Questionnaire - Total Score

    The SGRQ was asked with respect to the last one month as validated for acute exacerbations of COPD by Doll et al.

    Scale from 0 (no disability) to 100 (maximum disability).

    The SGRQ total score summarizes the impact of airway specific disease on overall health status. Scores range from zero (no impairment) to 100 (maximum impairment). Scores were calculated using the SGRQ scoring Algorithm.

  5. Change in Urinary Leukotriene (LTE4) Levels [ Time Frame: Baseline and 24 hours ]
    Change in natural log-transformed LTE4 (ng/mg Cr.) from Baseline to 24 Hours

  6. Change in Urinary Leukotriene (LTE4) Levels [ Time Frame: Baseline and 72 hours later ]
    Change in natural log-transformed LTE4 (ng/mg Cr.) from Baseline to 72 Hours

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Admitted to the hospital for a COPD exacerbation
  • FEV1 less than 60% of predicted level
  • At least 10 pack years of smoking

Exclusion Criteria:

  • Any uncontrolled systemic disease
  • Known hypersensitivity to zileuton
  • Asthma
  • Lobar pneumonia or pulmonary edema
  • Interstitial lung disease
  • Medical condition that is likely to limit survival to less than 30 days at the time of study entry
  • History of liver disease
  • Current use of theophylline
  • Participation in another clinical trial in the COPD Clinical Research Network
  • Incarceration
  • Institutionalization
  • Pregnant
  • History of a suicide attempt
  • Prior inpatient admission for a psychiatric disorder
  • Bipolar disorder


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00493974

Show Show 18 study locations
Sponsors and Collaborators
University of Minnesota
National Heart, Lung, and Blood Institute (NHLBI)
Layout table for investigator information
Study Chair: Prescott Woodruff, MD University of California at San Francisco
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Minnesota Identifier: NCT00493974    
Other Study ID Numbers: 0701M00621
U10HL074424 ( U.S. NIH Grant/Contract )
First Posted: June 29, 2007    Key Record Dates
Results First Posted: March 3, 2010
Last Update Posted: November 18, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by University of Minnesota:
Chronic Obstructive Pulmonary Disease
Length of Stay
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Lung Diseases, Obstructive
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Lipoxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Leukotriene Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists